Lets patients answer an online health questionnaire and receive a recurring prescription without a video call.
What stands out
- Most companies in its industry are production businesses; this one is an interface business
At a glance
Lets patients answer an online health questionnaire and receive a recurring prescription without a video call.
Hims & Hers runs a digital health platform where patients fill out structured questionnaires about conditions like hair loss or sexual health, a licensed physician in their specific jurisdiction reviews the responses and issues a prescription, and a DEA-registered partner pharmacy then dispenses the medication — with recurring refills, not one-off consultations, making up the bulk of revenue. The asynchronous design means one physician can handle far more patients per hour than a traditional video appointment, so the consultation side scales cheaply as volume grows. What cannot scale with money alone is the underlying licence network: each of the 56 jurisdictions the company operates in requires its own active physician credential, and medical board approval timelines run on their own schedules regardless of how much capital is spent trying to accelerate them. The whole fulfillment chain depends on both links holding simultaneously — if the DEA restricts telemedicine-initiated prescribing of controlled substances like testosterone, the physician licences remain valid but the partner pharmacies lose legal authority to dispense, and every affected prescription category stops generating revenue across all US jurisdictions at once.
How does this company make money?
The main income comes from monthly subscription fees that cover ongoing medical consultations and repeat prescriptions. The company also earns a markup on the prescription medications dispensed through its partner pharmacies. On top of that, it sells over-the-counter supplements and wellness products as one-time purchases shipped directly to customers.
What makes this company hard to replace?
A patient who wants to move to a competing platform has to start over: new consultation, new provider relationship, new intake process. Their medical records and prescription history from this platform are protected under HIPAA and cannot be transferred to a rival service. Because their refill cycle is built into this platform's pharmacy partnership, switching means a gap in medication access while everything is re-established elsewhere.
What limits this company?
The company operates across 56 places — all 50 US states plus the UK, Canada, Germany, France, Spain, and Ireland — and each one requires its own separately licensed physician and its own local compliance with telemedicine prescribing rules. Medical boards set their own approval timelines and no amount of money can speed them up. So adding a new country or replacing a physician who leaves is gated by bureaucratic schedules, not by hiring budgets.
What does this company depend on?
The company cannot operate without five things: active medical board licences for prescribing physicians in all 50 US states, partner pharmacies that hold DEA registrations for controlled substance dispensing, FDA-approved prescription medications for the sexual health and dermatology categories it serves, payment processing systems that handle recurring subscription billing, and HIPAA-compliant cloud infrastructure to store patient health records.
Who depends on this company?
Patients dealing with sexual dysfunction or hair loss — conditions many people prefer not to discuss face-to-face — would lose convenient access to medications like sildenafil or finasteride if this platform disappeared. Partner pharmacies would see their prescription fulfillment volumes drop because the platform is a significant source of new patients. Primary care physicians would likely absorb more of these sensitive consultations, since patients would have fewer specialized telehealth options.
How does this company scale?
The digital questionnaire and asynchronous review process can handle more patients without meaningfully increasing the time each physician spends per case — that part scales cheaply. What does not scale cheaply is expanding to new jurisdictions or replacing licensed providers, because medical board credentialing takes as long as it takes regardless of how much money is spent.
What external forces can significantly affect this company?
The biggest external threat is DEA regulatory change around telemedicine prescribing of controlled substances, including testosterone and weight-loss medications, which is already under active review. State medical boards can also shift their rules on cross-border telemedicine practice, which could shrink the number of jurisdictions a single physician can serve. For the European operations — in the UK, Germany, France, Spain, and Ireland — GDPR places strict requirements on how patient data is stored and handled.
Where is this company structurally vulnerable?
The DEA is actively reviewing whether telemedicine platforms can keep initiating prescriptions for controlled substances like testosterone and weight-loss medications. If the DEA tightens those rules, the company's physician licences would still be valid — but the partner pharmacies would lose the legal right to dispense those specific drugs. That would snap the chain between consultation and fulfillment for those medication categories across every US state at once.
Sign in to view price data.
Sign inStructural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph